On the pathogenic role of anti-CD4 antibody in poor CD4+ T cell recovery after antiretroviral therapy in HIV disease

抗 CD4 抗体在 HIV 疾病抗逆转录病毒治疗后 CD4 T 细胞恢复不良中的致病作用

基本信息

  • 批准号:
    9921289
  • 负责人:
  • 金额:
    $ 20.79万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-05-19 至 2022-04-30
  • 项目状态:
    已结题

项目摘要

Human immunodeficiency virus (HIV) disease has been significantly controlled following the introduction of antiretroviral therapy (ART) [1]. This treatment dramatically improves immune function, suppresses HIV viral replication, and decreases morbidity and mortality [1, 2]. However, up to 25% of virologically suppressed individuals (~111,000 people in USA) fail to restore their CD4+ T cells to counts > 350 cells/µL, even after long- term ART treatment and viral suppression [3], and increased morbidity and mortality have been observed in these patients [4-7]. Thymic fibrosis has been suggested a mechanism, and low nadir CD4+ T cell counts and T cell activation have been shown to associate with incomplete immune restoration after ART treatment [8-11], but mechanisms for immune non-response remain largely unknown. To better understand mechanisms of incomplete immune restoration, we performed a preliminary human study in 12 healthy controls, 17 immunologic responders (IRs) (aviremic and ART treated > 3 years, and CD4+ T cell counts > 500 cells/µL) and 11 immunologic non-responders (INRs) (aviremic and ART treated > 3 years, and CD4+ T cell counts < 350 cells/µL) [8]. Elevated plasma levels of anti-CD4 IgGs were found in patients compared to controls and correlated with blunted CD4+ T cell recovery. Furthermore, purified anti-CD4 IgGs from plasma of aviremic long-term ART-treated subjects with CD4+ T cell counts below 350 cells/µl, defined as “immunologic non- responders”, induced antibody-dependent NK cell-mediated cytotoxicity against CD4+ T cells. We hypothesize that heightened level of anti-CD4 Ab contributes to the pathogenesis of CD4+ T cell losses in HIV infection. If our hypothesis is correct, a therapeutic strategy that targeting autoreactive B cells or anti-CD4 Abs could potentially optimize ART treatment to improve CD4+ T cell recovery and reduce mortality and morbidity in treated HIV-infected patients. This study will also provide important information in HIV vaccine design.
人类免疫缺陷病毒(HIV)疾病在引入 抗逆转录病毒疗法(ART)[1]。这种疗法显著提高了免疫功能,抑制了HIV病毒 复制,并降低发病率和死亡率[1,2]。然而,高达25%的病毒学抑制 个人(在美国约111,000人)无法将他们的CD_4+T细胞恢复到计数为350个/µL,即使在长时间的 定期抗逆转录病毒治疗和病毒抑制[3],以及增加的发病率和死亡率已经观察到在 这些患者[4-7]。胸腺纤维化已被认为是一种机制,低水平的CD4+T细胞计数和 T细胞的激活已被证明与ART治疗后的不完全免疫恢复有关[8-11], 但免疫无反应的机制在很大程度上仍不清楚。为了更好地了解 不完全的免疫恢复,我们在12名健康对照中进行了初步的人体研究,17名 免疫应答者(无药和抗逆转录病毒治疗3年,CD 4+T细胞计数500个/µL) 11例免疫无反应(INRS)(无菌治疗和ART治疗3年,CD4+T细胞计数&lt; 350个细胞/微米L)[8]。与对照组相比,患者血浆中抗CD4Igs水平升高。 与钝化的CD4+T细胞恢复有关。此外,从无毒症小鼠血浆中提纯了抗CD4Igs 长期接受抗逆转录病毒治疗的CD_4+T细胞计数低于350个/微米的受试者L,定义为“免疫性非 应答者“,诱导抗体依赖的NK细胞介导的对CD4+T细胞的细胞毒作用。我们假设 高水平的抗CD4Ab参与了HIV感染中CD4+T细胞丢失的发病机制。如果 我们的假设是正确的,靶向自身反应性B细胞或抗CD4抗体的治疗策略可能 有可能优化ART治疗,以改善CD4+T细胞恢复并降低死亡率和发病率 治疗艾滋病毒感染者。这项研究还将为艾滋病毒疫苗的设计提供重要信息。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Wei Jiang其他文献

General Solution and Observability of Singular Differential Systems with Delay
时滞奇异微分系统的一般解与可观测性

Wei Jiang的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Wei Jiang', 18)}}的其他基金

Investigate Host Gene Isoforms Contributing to HIV Persistence in Cocaine Users
研究导致可卡因吸食者中艾滋病毒持续存在的宿主基因亚型
  • 批准号:
    10788990
  • 财政年份:
    2023
  • 资助金额:
    $ 20.79万
  • 项目类别:
Investigate the mechanism of autoreactive B cell-mediated immunological failure despite virologic suppression in HIV-infected individuals on antiretroviral therapy
研究尽管接受抗逆转录病毒治疗的 HIV 感染者出现病毒学抑制,但自身反应性 B 细胞介导的免疫失败的机制
  • 批准号:
    10595555
  • 财政年份:
    2022
  • 资助金额:
    $ 20.79万
  • 项目类别:
Investigate the mechanism of autoreactive B cell-mediated immunological failure despite virologic suppression in HIV-infected individuals on antiretroviral therapy
研究尽管接受抗逆转录病毒治疗的 HIV 感染者出现病毒学抑制,但自身反应性 B 细胞介导的免疫失败的机制
  • 批准号:
    10368232
  • 财政年份:
    2022
  • 资助金额:
    $ 20.79万
  • 项目类别:
Investigate B cell perturbations and immune reconstitution failure in response to antiretroviral therapy in HIV-infected cocaine users
调查感染 HIV 的可卡因使用者抗逆转录病毒治疗导致的 B 细胞扰动和免疫重建失败
  • 批准号:
    10547870
  • 财政年份:
    2022
  • 资助金额:
    $ 20.79万
  • 项目类别:
Investigate B cell perturbations and immune reconstitution failure in response to antiretroviral therapy in HIV-infected cocaine users
调查感染 HIV 的可卡因使用者抗逆转录病毒治疗导致的 B 细胞扰动和免疫重建失败
  • 批准号:
    10677040
  • 财政年份:
    2022
  • 资助金额:
    $ 20.79万
  • 项目类别:
Synergistic effect of HIV virions and bacterial LPS on memory B cell apoptosis
HIV病毒体和细菌LPS对记忆B细胞凋亡的协同作用
  • 批准号:
    8534019
  • 财政年份:
    2011
  • 资助金额:
    $ 20.79万
  • 项目类别:
Synergistic effect of HIV virions and bacterial LPS on memory B cell apoptosis
HIV病毒体和细菌LPS对记忆B细胞凋亡的协同作用
  • 批准号:
    8321994
  • 财政年份:
    2011
  • 资助金额:
    $ 20.79万
  • 项目类别:
Synergistic effect of HIV virions and bacterial LPS on memory B cell apoptosis
HIV病毒体和细菌LPS对记忆B细胞凋亡的协同作用
  • 批准号:
    8210255
  • 财政年份:
    2011
  • 资助金额:
    $ 20.79万
  • 项目类别:
Synergistic effect of HIV virions and bacterial LPS on memory B cell apoptosis
HIV病毒体和细菌LPS对记忆B细胞凋亡的协同作用
  • 批准号:
    8719000
  • 财政年份:
    2011
  • 资助金额:
    $ 20.79万
  • 项目类别:
Translational Pathology
转化病理学
  • 批准号:
    10447609
  • 财政年份:
    1995
  • 资助金额:
    $ 20.79万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 20.79万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了